EssilorLuxottica S.A.
Designs, manufactures and distributes ophthalmic lenses, frames, sunglasses, diagnostic imaging equipment and eyecare instruments globally under brands including Ray-Ban, Oakley and Essilor.
As of Oct 15, 2026
Summary
EssilorLuxottica S.A. is a global leader in eyewear design, manufacturing and distribution, combining lens technology with luxury and sports eyewear brands. The stock shows a neutral technical lean with recent momentum of 2.6% over the past month, though it has declined sharply by 51.5% over the last year, reflecting broader sector pressures. At a market capitalisation of €67.3 billion, the company remains a heavyweight in healthcare, currently trading at €148.10 per share.
Price history
As of Oct 14, 2026
Performance
+0.00%
+0.99%
+2.56%
-11.16%
-43.83%
-51.49%
As of Oct 14, 2026
Technical indicators
- 51.1
- 0.95Bullish
- 50: 152.85 · 200: 187.95Bearish
- €141.65 / €151.60
Technical Bias
EssilorLuxottica's technical indicators are split: MACD shows bullish momentum at 0.95, but the 50-day moving average trading below the 200-day average signals bearish trend structure, whilst RSI sits neutral at 51.1. This derived technical read suggests a lack of directional conviction, with price at €148.10 positioned between support at €141.65 and resistance at €151.60.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 14, 2026
Fundamentals
- €67.3B
- 27.43
- €5.35
- 8.52%
- +5.7%
- €3.77B
- 0.57
- €138.30 – €316.32
- 2.73%
- May 5, 2026
- Feb 11, 2027 (118 days)
As of Oct 16, 2026
Upcoming catalysts
- Earnings report
As of Oct 16, 2026
Latest news
As of Oct 16, 2026
MonkeyTrade's Take on EssilorLuxottica S.A.
Short-term outlook
EssilorLuxottica's short-term picture is mixed but leans cautiously constructive: MACD has turned bullish and the stock is up 2.6% over the past month, yet it still sits below both its 50-day (€152.85) and 200-day (€187.95) averages, with RSI at a neutral 51.1. The key test is €151.60 resistance; a clean break there would support further upside, while a slip back to €141.65 support would tilt the read bearish again. No earnings catalyst is imminent, so price action around these levels should drive the next few weeks.
Medium-term outlook
EssilorLuxottica's medium-term picture leans constructive but unremarkable: steady 5.7% revenue growth and an 8.5% margin support the business, while a 27.43 P/E suggests investors are already paying up for that quality, and the flat technical trend isn't adding conviction either way. The 2.7% dividend offers some ballast in the meantime. A clear re-acceleration in revenue growth would be the catalyst needed to justify the premium and shift this from a steady-as-she-goes story to a stronger one.
Key risks
- The shares are trading near the bottom of their 52-week range, well below the €316.32 high, which suggests the market has been pricing in significant concerns about growth or sentiment.
- A valuation of 27.43 times earnings leaves little room for disappointment, particularly if revenue growth of 5.7% year-on-year were to slow.
- The reported advanced talks for an Armani stake introduce integration and capital allocation uncertainty, as any acquisition could affect margins or require additional investment before benefits materialise.
- With a profit margin of 8.5%, the business has relatively thin buffers to absorb cost pressures or currency swings common in the eyewear and luxury goods space.
About EssilorLuxottica S.A.
EssilorLuxottica is a French healthcare company listed on Euronext Paris, operating in the medical instruments and supplies space. Formed from the merger of lens maker Essilor and eyewear group Luxottica, it holds a leading position in eyewear, combining prescription lens manufacturing with iconic frame brands. With a market capitalisation of €67.3B, it ranks among the larger names in its sector, reflecting its scale across both the optical and luxury eyewear markets.
The company's key figures give a sense of how the market currently views it. A price-to-earnings ratio of 27.43 suggests investors are paying a premium relative to current earnings, often a sign of expectations for steady or growing profitability. Meanwhile, a dividend yield of +2.7% shows it returns a portion of earnings to shareholders, offering an income element alongside any share price movement.
How to trade EssilorLuxottica S.A.
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.